Can needle and syringe programmes and opiate substitution therapy achieve substantial reductions in hepatitis C virus prevalence? Model projections for different epidemic settings
- 12 July 2012
- Vol. 107 (11), 1984-1995
- https://doi.org/10.1111/j.1360-0443.2012.03932.x
Abstract
Aims To investigate the impact of scaling-up opiate substitution therapy (OST) and high coverage needle and syringe programmes (100%NSPobtaining more sterile syringes than you inject) on HCV prevalence among injecting drug users (IDUs). Design Hepatitis C virus HCV transmission modelling using UK estimates for effect of OST and 100%NSP on individual risk of HCV infection. Setting Range of chronic HCV prevalent (20/40/60%) settings with no OST/100%NSP, and UK setting with 50% coverage of both OST and 100%NSP. Participants Injecting drug users. Measurements Decrease in HCV prevalence after 520 years due to scale-up of OST and 100%NSP to 20/40/60% coverage in no OST/100%NSP settings, or from 50% to 60/70/80% coverage in the UK setting. Findings For 40% chronic HCV prevalence, scaling-up OST and 100%NSP from 0% to 20% coverage reduces HCV prevalence by 13% after 10 years. This increases to a 24/33% relative reduction at 40/60% coverage. Marginally less impact occurs in higher prevalence settings over 10 years, but this becomes more pronounced over time. In the United Kingdom, without current coverage levels of OST and 100%NSP the chronic HCV prevalence could be 65% instead of 40%. However, increasing OST and 100%NSP coverage further is unlikely to reduce chronic prevalence to less than 30% over 10 years unless coverage becomes =80%. Conclusions Scaling-up opiate substitution therapy and high coverage needle and syringe programmes can reduce hepatitis C prevalence among injecting drug users, but reductions can be modest and require long-term sustained intervention coverage. In high coverage settings, other interventions are needed to further decrease hepatitis C prevalence. In low coverage settings, sustained scale-up of both interventions is needed.Keywords
This publication has 69 references indexed in Scilit:
- Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviewsThe Lancet, 2011
- Prevalence and predictors of transitions to and away from syringe exchange use over time in 3 US cities with varied syringe dispensing policiesDrug and Alcohol Dependence, 2010
- Acute Hepatitis C Virus Infection in Young Adult Injection Drug Users: A Prospective Study of Incident Infection, Resolution, and ReinfectionThe Journal of Infectious Diseases, 2009
- Potential impact of vaccination on the hepatitis C virus epidemic in injection drug usersEpidemics, 2009
- High dead-space syringes and the risk of HIV and HCV infection among injecting drug usersDrug and Alcohol Dependence, 2009
- A Meta-Analysis of Retention in Methadone Maintenance by Dose and Dosing StrategyThe American Journal of Drug and Alcohol Abuse, 2009
- Hepatitis C Virus Acquisition among Injecting Drug Users: A Cohort Analysis of a National Repeated Cross-sectional Survey of Needle and Syringe Program Attendees in Australia, 1995–2004Journal of Urban Health, 2008
- Higher syringe coverage is associated with lower odds of HIV risk and does not increase unsafe syringe disposal among syringe exchange program clientsDrug and Alcohol Dependence, 2007
- Major decline of hepatitis C virus incidence rate over two decades in a cohort of drug usersEuropean Journal of Epidemiology, 2007
- Hepatitis C virus infection among injecting drug users in Scotland: a review of prevalence and incidence data and the methods used to generate themEpidemiology and Infection, 2006